A detailed history of Bellevue Group Ag transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 9,300 shares of RCKT stock, worth $107,508. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,300
Previous 19,700 52.79%
Holding current value
$107,508
Previous $424,000 59.67%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.6 - $25.88 $183,040 - $269,152
-10,400 Reduced 52.79%
9,300 $171,000
Q1 2024

May 15, 2024

SELL
$26.16 - $30.74 $34,008 - $39,962
-1,300 Reduced 6.19%
19,700 $530,000
Q4 2023

Feb 14, 2024

BUY
$16.78 - $31.94 $352,380 - $670,740
21,000 New
21,000 $629,000
Q2 2023

Aug 14, 2023

BUY
$16.59 - $23.6 $315,210 - $448,400
19,000 Added 51.91%
55,600 $1.1 Million
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $567,300 - $833,016
36,600 New
36,600 $716,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $875M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.